Preclinical pharmacokinetics is the application of kinetic principles and mathematical models to quantitatively describe the dynamic patterns of drug absorption, distribution, metabolism and elimination processes over time. Experimental research follows the guiding principles of ICH, CFDA and FDA. We can design and conduct in vivo and in vitro pharmacokinetic tests according to customer needs, and provide customers with a complete set of pharmacokinetic evaluation and optimization services.

Pharmacokinetic in vitro studies

*Metabolic stability: microsomal stability, plasma stability, hepatocyte stability, S9 stability, UGT activity, aldehyde oxidase phenotype identification (AO), enzyme phenotype identification
*Distribution experiments: microsomal binding test, plasma Protein binding test, hepatocyte binding test, tissue protein binding test, whole blood-plasma partition test
*Permeability and transporters: Caco-2 cell permeability test, MDCK cell permeability test, P-gp substrate identification Test, P-gp inhibition test, hBCRP substrate identification test
*Drug interactions: CYP enzyme inhibition test (inhibition rate and IC50), TDI inhibition test

Pharmacokinetics in vivo studies
Provide in vivo PK experimental services, including various administration routes (such as oral, subcutaneous, intravenous, intraperitoneal injection, combination administration, etc.), pharmacokinetic experiments and toxicokinetic experiments on various tissues and experimental animals of different species (mice, rats, dogs, etc.) .